Ibandronate does not reduce the anabolic effects of PTH in ovariectomized rat tibiae: A microarchitectural and mechanical study

Bone

Volumn 48, Issue 5, 2011, Pages 1154-1163

  Yang, Xiao ^a   Chan, Yong Hoow ^a   Muthukumaran, Padmalosini ^a   DasDe, Shamal ^b   Teoh, Swee Hin ^a   Lee, Taeyong ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Additive effect; Bone morphology; Ibandronate; Micro CT; PTH

Indexed keywords

CARBOXY TERMINAL TELOPEPTIDE; IBANDRONIC ACID; PARATHYROID HORMONE[1-34]; PROCOLLAGEN; PROCOLLAGEN TYPE 1 AMINO TERMINAL PROPEPTIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOMECHANICS; BONE DENSITY; BONE STRENGTH; BONE STRUCTURE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEMALE; LOW DRUG DOSE; MECHANICAL STRESS; METAPHYSIS; MICRO-COMPUTED TOMOGRAPHY; NONHUMAN; OSTEOPOROSIS; OVARIECTOMY; PERIPHERAL QUANTITATIVE COMPUTED TOMOGRAPHY; RAT; STRESS STRAIN RELATIONSHIP; TIBIA;

ANIMALS; BIOLOGICAL MARKERS; BIOMECHANICS; BONE DENSITY; BONE REMODELING; COLLAGEN TYPE I; DIPHOSPHONATES; FEMALE; HUMANS; OSTEOGENESIS; OVARIECTOMY; PARATHYROID HORMONE; PEPTIDE FRAGMENTS; PEPTIDES; PROCOLLAGEN; RATS; RATS, SPRAGUE-DAWLEY; TIBIA; X-RAY MICROTOMOGRAPHY;

EID: 79954614496     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2011.02.007     Document Type: Article

References (62)

1. Currey J.D. Bone strength: what are we trying to measure?. Calcif Tissue Int 2001, 68:205-210.
2. Reginster J.-Y., Burlet N. Osteoporosis: a still increasing prevalence. Bone 2006, 38:4-9.
3. Kanis J.A., Johnell O., Oden A., Jonsson B., De Laet C., Dawson A. Risk of hip fracture according to the world health organization criteria for osteopenia and osteoporosis. Bone 2000, 27:585-590.
4. Iida-Klein A., Lu S.S., Cosman F., Lindsay R., Dempster D.W. Effects of cyclic vs. daily treatment with human parathyroid hormone (1-34) on murine bone structure and cellular activity. Bone 2007, 40:391-398.
5. Black D.M., Greenspan S.L., Ensrud K.E., Palermo L., McGowan J.A., Lang T.F., et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 2003, 349:1207-1215.
6. Black D.M., Bilezikian J.P., Ensrud K.E., Greenspan S.L., Palermo L., Hue T., et al. One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N Engl J Med 2005, 353:555-565.
7. Fleisch H. The bisphosphonate ibandronate, given daily as well as discontinuously, decreases bone resorption and increases calcium retention as assessed by 45Ca kinetics in the intact rat. Osteoporos Int 1996, 6:166-170.
8. Miller P.D., Mcclung M.R., Macovei L., Stakkestad J.A., Luckey M., Bonvoisin B., et al. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE Study. J Bone Miner Res 2005, 20:1315-1322.
9. Lambrinoudaki I., Vlachou S., Galapi F., Papadimitriou D., Papadias K. Once-yearly zoledronic acid in the prevention of osteoporotic bone fractures in postmenopausal women. Clin Interv Aging 2008, 3:445-451.
10. Felsenberg D., Miller P., Armbrecht G., Wilson K., Schimmer R.C., Papapoulos S.E. Oral ibandronate significantly reduces the risk of vertebral fractures of greater severity after 1, 2, and 3years in postmenopausal women with osteoporosis. Bone 2005, 37:651-654.
11. Muhlbauer R.C., Bauss F., Schenk R., Janner M., Bosies E., Strein K., et al. BM 21.0955, a potent new bisphosphonate to inhibit bone resorption. J Bone Miner Res 1991, 6:1003-1011.
12. Monier-Faugere M.C., Friedler R.M., Bauss F., Malluche H.H. A new bisphosphonate, BM 21.0955, prevents bone loss associated with cessation of ovarian function in experimental dogs. J Bone Miner Res 1993, 8:1345-1355.
13. Monier-Faugere M.-C., Geng Z., Paschalis E.P., Qi Q., Arnala I., Bauss F., et al. Intermittent and continuous administration of the bisphosphonate ibandronate in ovariohysterectomized beagle dogs: effects on bone morphometry and mineral properties. J Bone Miner Res 1999, 14:1768-1778.
14. Bauss F., Dempster D.W. Effects of ibandronate on bone quality: preclinical studies. Bone 2007, 40:265-273.
15. Cosman F., Nieves J., Woelfert L., Shen V., Lindsay R. Alendronate does not block the anabolic effect of PTH in postmenopausal osteoporotic women. J Bone Miner Res 1998, 13:1051-1055.
16. Garcés C., García L.-E. Combination of anabolic and antiresorptive agents for the treatment of osteoporosis. Maturitas 2006, 54:47-54.
17. Finkelstein J.S., Hayes A., Hunzelman J.L., Wyland J.J., Lee H., Neer R.M. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 2003, 349:1216-1226.
18. Johnston S., Andrews S., Shen V., Cosman F., Lindsay R., Dempster D.W., et al. The effects of combination of alendronate and human parathyroid hormone (1-34) on bone strength are synergistic in the lumbar vertebra and additive in the femur of C57BL/6J mice. Endocrinology 2007, 148:4466-4474.
19. Rittmaster R.S., Bolognese M., Ettinger M.P., Hanley D.A., Hodsman A.B., Kendler D.L., et al. Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocrinol Metab 2000, 85:2129-2134.
20. Hildebrand T., Laib A., Müller R., Dequeker J., Rüegsegger P. Direct three-dimensional morphometric analysis of human cancellous bone: microstructural data from spine, femur, iliac crest, and calcaneus. J Bone Miner Res 1999, 14:1167-1174.
21. Stürmer E.K., Seidlová-Wuttke D., Sehmisch S., Rack T., Wille J., Frosch K.H., et al. Standardized bending and breaking test for the normal and osteoporotic metaphyseal tibias of the rat: effect of estradiol, testosterone, and raloxifene. J Bone Miner Res 2006, 21:89-96.
22. Wilkin T.J., Devendra D., Dequeker J., Luyten F.P. Bone densitometry is not a good predictor of hip fracture. Br Med J 2001, 323:795-799.
23. Cefalu C.A. Is bone mineral density predictive of fracture risk reduction?. Curr Med Res Opin 2004, 20:341-349.
24. Kumasaka S., Asa K., Kawamata R., Okada T., Miyake M., Kashima I. Relationship between bone mineral density and bone stiffness in bone fracture. Oral Radiol 2005, 21:38-40.
25. Watts N., Bockman R., Smith C., Li Z., Eastell R., Pack S., Lindsay R. BMD change explains only a fraction of the observed fracture risk reduction in risendronate treated patients. Osteoporos Int 2000, 11:S203.
26. Campbell G.M., Buie H.R., Boyd S.K. Signs of irreversible architectural changes occur early in the development of experimental osteoporosis as assessed by in vivo micro-CT. Osteoporos Int 2008, 19:1409-1419.
27. Gittens S.A., Wohl G.R., Zernicke R.F., Matyas J.R., Morley P., Uludag H. Systemic bone formation with weekly PTH administration in ovariectomized rats. J Pharm Pharm Sci 2004, 7:27-36.
28. Bauss F., Wagner M., Hothorn L.H. Total administered dose of ibandronate determines its effects on bone mass and architecture in ovariectomized aged rats. J Rheumatol 2002, 29:990-998.
29. Boyd S.K., Davison P., Müller R., Gasser J.A. Monitoring individual morphological changes over time in ovariectomized rats by in vivo micro-computed tomography. Bone 2006, 39:854-862.
30. Stürmer E., Sehmisch S., Tezval M., Tezval H., Rack T., Boekhoff J., et al. Effect of testosterone, raloxifene and estrogen replacement on the microstructure and biomechanics of metaphyseal osteoporotic bones in orchiectomized male rats. World J Urol 2009, 27:547-555.
31. Barbier A., Martel C., de Vernejoul M.C., Tirode F., Nys M., Mocaer G., et al. The visualization and evaluation of bone architecture in the rat using three-dimensional X-ray microcomputed tomography. J Bone Miner Metab 1999, 17:37-44.
32. Teo J.C.M., Si-Hoe K.M., Keh J.E.L., Teoh S.H. Relationship between CT intensity, micro-architecture and mechanical properties of porcine vertebral cancellous bone. Clin Biomech 2006, 21:235-244.
33. Laib A., Barou O., Vico L., Lafage-Proust M., Alexandre C., Rügsegger P. 3D micro-computed tomography of trabecular and cortical bone architecture with application to a rat model of immobilisation osteoporosis. Med Biol Eng Comput 2000, 38:326-332.
34. Schaller S., Henriksen K., Sveigaard C., Heegaard A.-M., Hélix N., Stahlhut M., et al. The chloride channel inhibitor NS3736 prevents bone resorption in ovariectomized rats without changing bone formation. J Bone Miner Res 2004, 19:1144-1153.
35. Rissanen J., Suominen M., Peng Z., Morko J., Rasi S., Risteli J., et al. Short-term changes in serum PINP predict long-term changes in trabecular bone in the rat ovariectomy model. Calcif Tissue Int 2008, 82:155-161.
36. Bauss F., Lalla S., Endele R., Hothorn L.A. Effects of treatment with ibandronate on bone mass, architecture, biomechanical properties, and bone concentration of ibandronate in ovariectomized aged rats. J Rheumatol 2002, 29:2200-2208.
37. Kokoroghiannis C., Charopoulos I., Lyritis G., Raptou P., Karachalios T., Papaioannou N. Correlation of pQCT bone strength index with mechanical testing in distraction osteogenesis. Bone 2009, 45:512-516.
38. Ward K.A., Roberts S.A., Adams J.E., Mughal M.Z. Bone geometry and density in the skeleton of pre-pubertal gymnasts and school children. Bone 2005, 36:1012-1018.
39. Hasegawa Y., Schneider P., Reiners C. Age, sex, and grip strength determine architectural bone parameters assessed by peripheral quantitative computed tomography (pQCT) at the human radius. J Biomech 2001, 34:497-503.
40. Kharode Y.P., Sharp M.C., Bodine P.V.N. Utility of the ovariectomized rat as a model for human osteoporosis in drug discovery. Meth Mol Biol 2008, 455:111-124.
41. Stürmer E., Sehmisch S., Rack T., Wenda E., Seidlova-Wuttke D., Tezval M., et al. Estrogen and raloxifene improve metaphyseal fracture healing in the early phase of osteoporosis. A new fracture-healing model at the tibia in rat. Langenbecks Arch Surg 2010, 395:163-172.
42. Lane N.E., Kumer J.L., Majumdar S., Khan M., Lotz J., Stevens R.E., et al. The effects of synthetic conjugated estrogens, A (cenestin) on trabecular bone structure and strength in the ovariectomized rat model. Osteoporos Int 2002, 13:816-823.
43. Flieger J., Karachalios T., Khaldi L., Raptou P., Lyritis G. Mechanical stimulation in the form of vibration prevents postmenopausal bone loss in ovariectomized rats. Calcif Tissue Int 1998, 63:510-514.
44. Rubinacci A., Marenzana M., Cavani F., Colasante F., Villa I., Willnecker J., et al. Ovariectomy sensitizes rat cortical bone to whole-body vibration. Calcif Tissue Int 2008, 82:316-326.
45. Sehmisch S., Galal R., Kolios L., Tezval M., Dullin C., Zimmer S., et al. Effects of low-magnitude, high-frequency mechanical stimulation in the rat osteopenia model. Osteoporos Int 2009, 20:1999-2008.
46. Wang Z., Goh J., De S.D., Ge Z., Ouyang H., Chong J.S.W., et al. Efficacy of bone marrow-derived stem cells in strengthening osteoporotic bone in a rabbit model. Tissue Eng 2006, 12:1753-1761.
47. Papapoulos S.E. Bone remodelling and antifracture efficacy of oral bisphosphonate therapy. Bone 2007, 41:S32-S.
48. Smith S.Y., Recker R.R., Hannan M., Müller R., Bauss F. Intermittent intravenous administration of the bisphosphonate ibandronate prevents bone loss and maintains bone strength and quality in ovariectomized cynomolgus monkeys. Bone 2003, 32:45-55.
49. Poole K.E.S., Reeve J. Parathyroid hormone-a bone anabolic and catabolic agent. Curr Opin Pharmacol 2005, 5:612-617.
50. Frolik C.A., Black E.C., Cain R.L., Satterwhite J.H., Brown-Augsburger P.L., Sato M., et al. Anabolic and catabolic bone effects of human parathyroid hormone (1-34) are predicted by duration of hormone exposure. Bone 2003, 33:372-379.
51. Binkley N., Silverman S., Simonelli C., Santiago N., Kohles J., Dasic G., Sunyecz J. Monthly ibandronate suppresses serum CTX-I within 3days and maintains a monthly fluctuating pattern of suppression. Osteoporos Int 2009, 20:1595-1601.
52. Black D.M., Bouxsein M.L., Palermo L., McGowan J.A., Newitt D.C., Rosen E., et al. Randomized trial of once-weekly parathyroid hormone (1-84) on bone mineral density and remodeling. J Clin Endocrinol Metab 2008, 93:2166-2172.
53. Yamamoto K., Watanabe T., Gochou T., Saito K. Comparative study of human-PTH (1-84) and human-PTH (1-34) in the chick hypercalcemia bioassay. J Bone Miner Metab 1994, 12:S135-S137.
54. Samadfam R., Xia Q., Goltzman D. Co-treatment of PTH with osteoprotegerin or alendronate increases its anabolic effect on the skeleton of oophorectomized mice. J Bone Miner Res 2007, 22:55-63.
55. Vahle J.L., Sato M., Long G.G., Young J.K., Francis P.C., Engelhardt J.A., et al. Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2years and relevance to human safety. Toxicol Pathol 2002, 30:312-321.
56. Sato M., Ma Y.L., Hock J.M., Westmore M.S., Vahle J., Villanueva A., Turner C.H. Skeletal efficacy with parathyroid hormone in rats was not entirely beneficial with long-term treatment. J Pharmacol Exp Ther 2002, 302:304-313.
57. Crandall C. Parathyroid hormone for treatment of osteoporosis. Arch Intern Med 2002, 162:2297-2309.
58. Uzawa T. Therapeutic agents for disorders of bone and calcium metabolism-parathyroid hormone in weekly subcutaneous injection. Clin Calcium 2007, 17:56-62.
59. Komatsu D.E., Brune K.A., Liu H., Schmidt A.L., Han B., Zeng Q.Q., et al. Longitudinal in vivo analysis of the region-specific efficacy of parathyroid hormone in a rat cortical defect model. Endocrinology 2009, 150:1570-1579.
60. Co ELa. United States Package Insert: Forteo [teriparatide(rDNA origin) injection]. Indianapolis, IN; 2002.
61. Cipriano C., Issack P., Shindle L., Werner C., Helfet D., Lane J. Recent advances toward the clinical application of PTH (1-34) in fracture healing. HSS J 2009, 5:149-153.
62. Cosman F., Nieves J., Zion M., Woelfert L., Luckey M., Lindsay R. Daily and cyclic parathyroid hormone in women receiving alendronate. N Engl J Med 2005, 353:566-575.